NCT03015896

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Active, enrolled Phase 1, PHASE2 Last updated 29 September 2025

What this trial tests

Phase 1, PHASE2 trial testing Laboratory Biomarker Analysis in Grade 3a Follicular Lymphoma in 36 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

14 February 2017

Primary endpoint
9 August 2026

31 December 2026

Quick facts

Lead sponsor	David Bond, MD
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	14 February 2017
Primary completion	9 August 2026
Estimated completion	31 December 2026
Sites	2 locations across United States

Drugs / interventions tested

• Laboratory Biomarker Analysis — full drug profile →
• Lenalidomide — full drug profile →
• Nivolumab (nivolumab) — full drug profile →

Conditions studied

• Grade 3a Follicular Lymphoma — all drugs for Grade 3a Follicular Lymphoma →
• Recurrent Burkitt Lymphoma — all drugs for Recurrent Burkitt Lymphoma →
• Recurrent Diffuse Large B-Cell Lymphoma — all drugs for Recurrent Diffuse Large B-Cell Lymphoma →
• Recurrent Follicular Lymphoma — all drugs for Recurrent Follicular Lymphoma →

Sponsor

David Bond, MD

Who can join

18 and older, any sex, with Grade 3a Follicular Lymphoma or Recurrent Burkitt Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This I/II trial studies the side effects and best dose of lenalidomide when given together with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and lenalidomide may work better in treating patients with non-Hodgkin or Hodgkin lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Advances in targeted therapy for malignant lymphoma.
   Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2
2. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
   Merryman RW, Armand P, Wright KT, Rodig SJ. · · 2017 · cited 87× · PMID 29296917 · DOI 10.1182/bloodadvances.2017012534
3. Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.
   Cao Y, Xie L, Shi F, Tang M, et al · · 2021 · cited 86× · PMID 33436584 · DOI 10.1038/s41392-020-00376-4
4. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
   Zhang J, Zhang J, Medeiros LJ, Young KH. · · 2018 · cited 65× · PMID 30250823 · DOI 10.3389/fonc.2018.00351
5. Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research.
   Varayathu H, Sarathy V, Thomas BE, Mufti SS, et al · · 2021 · cited 62× · PMID 34123767 · DOI 10.3389/fonc.2021.559161
6. Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
   Hatic H, Sampat D, Goyal G. · · 2021 · cited 50× · PMID 34277837 · DOI 10.21037/atm-20-6833
7. Immune checkpoint inhibitors in the treatment of virus-associated cancers.
   Gao P, Lazare C, Cao C, Meng Y, et al · · 2019 · cited 47× · PMID 31182108 · DOI 10.1186/s13045-019-0743-4
8. Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
   Armengol M, Santos JC, Fernández-Serrano M, Profitós-Pelejà N, et al · · 2021 · cited 38× · PMID 33430146 · DOI 10.3390/cancers13020214